Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

PT-141

FDA Approved (Vyleesi)

Neuropeptide · Palatin Technologies (Vyleesi)

Melanocortin-4 receptor agonist approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on nervous system pathways rather than on the vascular system.

About

Mechanism

Synthetic cyclic heptapeptide, non-selective melanocortin receptor agonist with preferential activity at MC4R. Activates central nervous system pathways involved in sexual arousal. Does not act on PDE5 or the vasculature.

Half-Life

Approximately 2.5 hours

Route

subcutaneous

Frequency

As needed, max 1 dose per 24 h

Clinical Dosing

1.75 mgas needed, max 1 dose per 24 h

Only Vyleesi (bremelanotide 1.75 mg autoinjector) is FDA-approved, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. Other formulations and uses are research or compounded only.

FDA-approved dose: 1.75 mg SC as needed, at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours, not more than 8 doses per month (Vyleesi label).

Titration Protocols

Vyleesi Label (HSDD, premenopausal women)

Source: Vyleesi (bremelanotide) Prescribing Information, FDA 2019

Dose	Duration	Draw (1 mg vial in 2mL)	Notes
1.75 mg	Maintenance	3.50 mL (350 units)	SC as needed, ≥45 min before activity. Max 1 dose / 24 h, max 8 doses / month.

Available Vial Sizes

1 mg

1 mg vial

2 mg

2 mg vial

5 mg

5 mg vial

Citations

[1]Vyleesi (bremelanotide injection) — Prescribing Information. FDA / Palatin Technologies. Link(Reviewed: 2026-04-14)
[2]Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 134(5), 899-908. Link(Reviewed: 2026-04-14)